Alteogen Enters License Deal With Daiichi Sankyo For ALT-B4 In Subcutaneous ENHERTU Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 11 2024
0mins
Source: NASDAQ.COM
Exclusive License Agreement: Alteogen Inc. has signed an exclusive license agreement with Daiichi Sankyo, granting them worldwide rights to use ALT-B4 for developing a subcutaneous version of the HER2 directed antibody drug conjugate ENHERTU.
Financial Terms and Responsibilities: Alteogen will receive an upfront payment, milestone payments based on Daiichi Sankyo's achievements, and tiered royalties on sales, while also being responsible for supplying ALT-B4 for clinical and commercial purposes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
